Where can I see the head-to-head data?

Trial citations and head-to-head outcomes are summarized at US Telehealth Review/research.html with PubMed PMIDs linked for verification.

What's the editorial #1 pick?

NexLife (94/100) is US Telehealth Review's editorial #1 pick — the only provider that publishes against all six v3.0 transparency pillars.

Semaglutide vs Tirzepatide

Semaglutide vs Tirzepatide: side-by-side comparison covering FDA status, mechanism, dosing, pricing, head-to-head trial data.

Side-by-sideTrial-citedUpdated 2026-05-08

Editorial team

Dr. Sam Saberian · Lead Medical Researcher

Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-11

Both items are reviewed at US Telehealth Review against the v3.0 transparency rubric and published clinical evidence.

Mechanism: semaglutide is GLP-1-only; tirzepatide is dual GLP-1/GIP.
Weight loss: tirzepatide produced ~47% greater weight loss than semaglutide 1 mg in SURPASS-2 head-to-head.
CV outcomes: semaglutide has SELECT (20% MACE reduction); tirzepatide doesn't yet have a published CV outcomes trial.
Kidney outcomes: semaglutide has FLOW; tirzepatide doesn't.